10-QPeriod: Q2 FY2015

AbbVie Inc. Quarterly Report for Q2 Ended Jun 30, 2015

Filed August 7, 2015For Securities:ABBV

Summary

AbbVie Inc. reported strong financial results for the second quarter and first half of 2015, demonstrating significant revenue growth and improved profitability. Net revenues increased by 11% year-over-year to $5.5 billion for the quarter and 19% to $10.5 billion for the first half, primarily driven by the continued robust performance of HUMIRA and the successful global launch of AbbVie's interferon-free HCV treatment. The acquisition of Pharmacyclics in May 2015 for approximately $20.8 billion marked a transformative event, significantly expanding AbbVie's oncology portfolio with the addition of IMBRUVICA and contributing $107 million in net revenues post-acquisition. This strategic move is expected to accelerate revenue and earnings growth, further diversifying the company's revenue base. Operationally, AbbVie achieved a notable improvement in gross margin to 82% for the first half of 2015, up from 77% in the prior year, attributed to a favorable product mix and operational efficiencies. The company also continued to invest in its robust pipeline, with over 40 compounds in clinical development, particularly in immunology, oncology, and virology. Despite increased R&D spending and integration costs associated with the Pharmacyclics acquisition, AbbVie managed its selling, general, and administrative expenses effectively, with these costs representing 30% of net revenues for the first half. The company also returned significant capital to shareholders through $1.6 billion in cash dividends and initiated an accelerated share repurchase program of $5.0 billion, underscoring its strong cash flow generation.

Financial Highlights

51 data points
Beta

Revenue

$5.47B

83.3% Gross Margin

Net Income

$1.37B

24.9% Net Margin

EPS (Diluted)

$0.83

Total Assets

$53.85B

Cash & Equivalents

$7.40B

Free Cash Flow

$1.72B

Financial Statements
Beta
Revenue$5.47B
Cost of Revenue$916.00M
Gross Profit$4.56B
SG&A Expenses$1.70B
Operating Expenses$3.62B
Operating Income$1.85B
Interest Expense$172.00M
Net Income$1.37B
EPS (Basic)$0.84
EPS (Diluted)$0.83
Shares Outstanding (Basic)1.62B
Shares Outstanding (Diluted)1.63B

Key Highlights

  • 1AbbVie completed the $20.8 billion acquisition of Pharmacyclics, adding IMBRUVICA to its portfolio and significantly strengthening its oncology presence.
  • 2Net revenues grew 11% year-over-year to $5.5 billion for Q2 2015 and 19% to $10.5 billion for H1 2015 (on a constant currency basis).
  • 3HUMIRA demonstrated continued strong performance, with global net revenues up 16% in Q2 and 21% in H1 (on a constant currency basis).
  • 4Gross margin improved to 82% for H1 2015, up from 77% in H1 2014, driven by favorable product mix and operational efficiencies.
  • 5The company's R&D pipeline remains robust with over 40 compounds in clinical development, including significant advancements in oncology and immunology.
  • 6AbbVie paid $1.6 billion in cash dividends and initiated a $5.0 billion accelerated share repurchase program in H1 2015, demonstrating strong capital return to shareholders.
  • 7Net earnings for H1 2015 were $2.39 billion, or $1.47 per diluted share.

Frequently Asked Questions

The acquisition of Pharmacyclics for approximately $20.8 billion in May 2015 significantly impacted AbbVie's balance sheet and operations. It resulted in substantial goodwill and intangible assets, primarily related to IMBRUVICA. Post-acquisition, IMBRUVICA contributed $107 million in net revenues for the partial second quarter and is expected to be a significant driver of future revenue and earnings growth. The acquisition also led to increased interest expense due to debt financing and integration costs.

HUMIRA continued to be AbbVie's top-selling product, showing strong growth in both the US and international markets. For the first six months of 2015, global HUMIRA net revenues increased by 21% on a constant currency basis, driven by market growth, increased market share, and favorable pricing. The company is also pursuing new indications for HUMIRA to extend its market leadership.

AbbVie financed the Pharmacyclics acquisition and an accelerated share repurchase program through a significant issuance of senior notes totaling $16.7 billion. The company has a strong focus on capital allocation, evidenced by its consistent payment of cash dividends, which increased during this period, and its substantial share repurchase programs, including the recent $5.0 billion accelerated share repurchase. AbbVie expects to generate strong operating cash flows to fund its operations, pipeline development, and shareholder returns.

The filing highlights that realizing the full benefits of the Pharmacyclics merger depends on successfully commercializing IMBRUVICA, including meeting market demand, ensuring manufacturing and supply chain efficiency, and navigating competitive pressures and potential label changes. Additionally, the increased debt burden from the acquisition presents a risk, potentially impacting cash flow available for operations and growth, and could lead to credit rating downgrades.